On Thursday, the U.S. Food and Drug Administration (FDA) approved Crinetics Pharmaceuticals, Inc.'s (NASDAQ: CRNX ) Palsonify (paltusotine) for the first-line treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option.